EcoDrugPlus

C-C Motif Chemokine Receptor 1

Ensembl ID : ENSLAFG00000011890
Gene Symbol: CCR1
2 External references
299 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

C-C Motif Chemokine Receptor 2

Ensembl ID : ENSLAFG00000029528
Gene Symbol: CCR2
2 External references
286 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

C-C Motif Chemokine Receptor 4

Ensembl ID : ENSLAFG00000001081
Gene Symbol: CCR4
2 External references
254 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

C-C Motif Chemokine Receptor 5

Ensembl ID : ENSLAFG00000025726
Gene Symbol: CCR5
2 External references
298 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

C-C Motif Chemokine Receptor 9

Ensembl ID : ENSLAFG00000007501
Gene Symbol: CCR9
2 External references
262 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

C-X-C Motif Chemokine Ligand 8

Ensembl ID : ENSLAFG00000000483
Gene Symbol: CXCL8
2 External references
183 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

C-X-C Motif Chemokine Receptor 1

Ensembl ID : ENSLAFG00000027224
Gene Symbol: CXCR1
2 External references
158 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

C-X-C Motif Chemokine Receptor 4

Ensembl ID : ENSLAFG00000006285
Gene Symbol: CXCR4
2 External references
283 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

C-Type Lectin Domain Family 4 Member C

Ensembl ID : ENSLAFG00000010198
Gene Symbol: CLEC4C
2 External references
731 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cf Transmembrane Conductance Regulator

Ensembl ID : ENSLAFG00000005753
Gene Symbol: CFTR
2 External references
216 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Dna Methyltransferase 1

Ensembl ID : ENSLAFG00000002818
Gene Symbol: DNMT1
2 External references
206 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Dna Topoisomerase I

Ensembl ID : ENSLAFG00000011045
Gene Symbol: TOP1
2 External references
270 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).